EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Comparison of Rosuvastatin 5 mg versus Atorvastatin 20 mg in Patients with Dyslipidemia: A Naturalistic Clinical Study

Pramod Kumar Sharma, Ajay Gupta, Vikram Singh, Naresh Kumar Midha, Bharat Kumar

Journal of Primary Care Specialties · 2026-05 · 7 (2) · 62-67

DOI: 10.4103/jopcs.jopcs_2_26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Primary Care Specialties, online erschienen am 21.04.2026. Verfasst von Pramod Kumar Sharma und 4 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is no head-to-head trial comparing rosuvastatin 5 mg and atorvastatin 20 mg for the treatment of dyslipidemia. There is considerable cost difference between the two therapies and in a country where out-of-pocket expenditure is high, we plan to compare the safety, efficacy, and cost-effectiveness of rosuvastatin 5 mg and atorvastatin 20 mg in patients with dyslipidemia. Materials and Methods: We compared rosuvastatin 5 mg ( n = 33) with atorvastatin 20 mg ( n = 31) in adult (>18 years), newly diagnosed, treatment naive patients visiting medicine outpatient department who are eligible for statin therapy. Both the drugs were administered once daily. Lipid profile was done at baseline and after 6 weeks of therapy. The primary efficacy endpoint was the percentage change from baseline low-density lipoprotein cholesterol (LDL-C) levels after 6 weeks.

Results

Sixty-four patients completed the study. Both treatments resulted in a significant reduction from baseline in LDL-C, total cholesterol (TC), and triglycerides (TGs). The percentage reduction in TC, LDL-C, and TGs was 27%, 37%, and 21% in rosuvastatin group as compared to 30%, 39%, and 25% in the atorvastatin group, respectively. Cost-effectiveness analysis showed that atorvastatin costs twice as that of rosuvastatin for the same amount of benefit.

Conclusions

The study found both the treatments are comparable in terms of safety and efficacy. The higher cost-effectiveness of rosuvastatin 5 mg as compared to atorvastatin 20 mg, makes the former preferred initial treatment of dyslipidemia.

Zitieren

APA

Sharma, P. K., Gupta, A., Singh, V., Midha, N. K., & Kumar, B. (2026). Comparison of Rosuvastatin 5 mg versus Atorvastatin 20 mg in Patients with Dyslipidemia: A Naturalistic Clinical Study. Journal of Primary Care Specialties, 7(2), 62-67. https://doi.org/10.4103/jopcs.jopcs_2_26

Vancouver

Sharma PK, Gupta A, Singh V, Midha NK, Kumar B. Comparison of Rosuvastatin 5 mg versus Atorvastatin 20 mg in Patients with Dyslipidemia: A Naturalistic Clinical Study. Journal of Primary Care Specialties. 2026;7(2):62-67. doi:10.4103/jopcs.jopcs_2_26

BibTeX
@article{Sharma2026,
  author = {Sharma, Pramod Kumar and Gupta, Ajay and Singh, Vikram and Midha, Naresh Kumar and Kumar, Bharat},
  title = {Comparison of Rosuvastatin 5 mg versus Atorvastatin 20 mg in Patients with Dyslipidemia: A Naturalistic Clinical Study},
  journal = {Journal of Primary Care Specialties},
  year = {2026},
  volume = {7},
  number = {2},
  pages = {62--67},
  doi = {10.4103/jopcs.jopcs_2_26}
}
Kostenlos starten →